SAN DIEGO (AP) - SAN DIEGO (AP) - DMK Pharmaceuticals Corporation (DMK) on Tuesday reported a loss of $1.4 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 20 cents. Losses, adjusted to account for discontinued operations, came to 25 cents per share. The biopharmaceutical company posted revenue of $9,100 in the period. Its adjusted revenue was $9,000. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on DMK at https://www.zacks.com/ap/DMK
Adamis Pharmaceuticals is a California-based biotechnology company that discovers and develops novel therapeutics for the treatment of neuro-based disorders.